feed,title,long_url,short_url
MedRxiv,Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination,https://medrxiv.org/cgi/content/short/2024.01.23.24301671v1?rss=1,https://da.gd/D0JmL
